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abstract: Recently, a number of commercial companies are offering preconceptional carrier tests directly-to-consumers. This offer
raises a number of concerns and issues above and beyond those encountered with preconceptional tests offered within the traditional
health care setting. In order to bring some of these issues to light and to initiate dialogue on this topic, this article discusses the following
issues: the current offer of preconceptional carrier tests (until the end of 2010) through online commercial companies; the implications for
the informed consent procedure and the need for good information; the need for medical supervision and follow-up; and the appropriate use
of existing resources. The article concludes with some reﬂections about the potential sustainability of the offer of preconceptional carrier
tests directly-to-consumers.
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Introduction
Identifying carriers of autosomal recessive or X-linked disorders
before pregnancy has the potential to beneﬁt prospective parents.
Couples can become aware of the possible genetic risks to future off-
spring and of the reproductive options available. These options include
not only prenatal diagnosis followed (or not) by termination of the
pregnancy in case of an affected fetus or by coming to terms with
the risk, but also the choices of using preimplantation genetic diagno-
sis, using donor sperm or oocytes, seeking adoption or refraining from
having children. In some culturally related marriage practices, it could
also result in choosing a different partner.
There are two approaches to the identiﬁcation of carriers: carrier
screening and carrier testing. Carrier screening is deﬁned as the detec-
tion of carrier status in persons who do not have an a priori increased
risk for having a child with a certain disease, whereas with carrier
testing, the persons do have a higher a priori risk based on their or
their partners’ personal or family history (Castellani et al., 2010).
Carrier screening can be offered on an individual basis, but also as
an organized screening programme, either during or before pregnancy.
While most screening programmes in health care aim to prevent, treat
and alleviate disease, above and beyond these aims, the particular goal
of preconceptional carrier screening is to strengthen reproductive
autonomy and informed decision-making. If offered preconceptionally,
this can mean less time constraints, less pressure and less emotional
stress than when a test is performed during pregnancy (Bombard
et al., 2010)
Internationally,thepotential ofpreconceptional carrierscreeninghas
been studied extensively for cystic ﬁbrosis (CF) (Bekker et al., 1993;
Tamboretal.,1994;Axworthyetal.,1996;Honnoretal.,2000;Henne-
manetal.,2001;Lakemanetal.,2009)andhaemoglobinopathies(HbPs)
(Modell et al., 1998; Keskin et al., 2000; Lakeman et al., 2009). These
studies have repeatedly revealed positive attitudes towards CF carrier
screening from health care providers (Poppelaars et al., 2004a; McCla-
ren et al., 2008), patients and their relatives (Poppelaars et al., 2003)
and from the general public (Poppelaars et al., 2004c). Furthermore,
preconceptional carrier screening for CF for couples with no family
historyofCFwasrecommendedadecadeagobytheNationalInstitutes
of Health (NIH) (National Institutes of Health, 1999), the American
College of Medical Genetics (ACMG) and the American College of
Obstetricians and Gynaecologists (ACOG) (Grody et al., 2001).
Despite this, screening is not currently offered in most countries.
Carrier testing for disorders such as CF is still usually restricted to
families and partners of CF patients and carriers.
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in Cyprus and Sardinia) and speciﬁc communities (e.g. carrier screening
for Ashkenazi Jews), traditional healthcare systems have hesitated to
implement carrier screening programmes for the entire population of
couples planning a pregnancy. Various concerns underlie this stance,
including the psychological impact (Axworthy et al., 1996) and risk of
stigmatization/discrimination of being a carrier (McQueen, 2002),
impairment of the freedom of choice because of the undue pressure
on individual choice (Godard et al., 2003), medicalization (Poppelaars
et al., 2004c), the fact that couples are difﬁcult to reach before con-
ception (Lakeman et al., 2009), and provider-related barriers such as a
lackof familiarity with genetics and selection criteria for offering screen-
ing (Morgan et al., 2004).
Recently, commercial companies have been offering preconcep-
tional carrier tests directly-to-consumers. These direct-to-consumer
(DTC) tests provide information about monogenic diseases and the
risk of having affected offspring. DTC genetic testing is often deﬁned
as the offer and/or marketing of genetic tests directly to the public
without the intermediary of a health care professional from the tra-
ditional health care system. As has been suggested by the Human
Genetics Commission, however, we also include in this discussion
‘tests that are commissioned by the consumer’ from a commercial
company outside the traditional health care system ‘but where a
medical practitioner or a health professional is involved in the pro-
vision of the service’ (Human Genetics Commission, 2010). The avail-
ability of DTC genetic testing services in general has created a huge
debate about the desirability of these activities (Howard and Borry,
2008; Hunter et al., 2008; Kaye, 2008). However, until now, these dis-
cussions have mainly focused on the commercial DTC offer of
genome-wide-testing; a service which offers individual risk assess-
ments for common disorders (Janssens et al., 2008; Melzer et al.,
2008) with limited or no medical or health beneﬁts to the individual
user. Various concerns were raised with regard to this DTC offer of
genetic tests, including, among others, concerns related to the validity
and utility of tests offered, the absence of individualized medical super-
vision, the lack of an adequate consent procedure, the absence and/
or quality of pre- and post-test genetic counselling, the inappropriate
testing of minors, the respect for privacy and the potential burden on
public health resources.
Because of the great heterogeneity in types of DTC genetic tests,
and the fact that the consequences of their results vary widely, a
one-size-ﬁts-all approach is not appropriate for all DTC genetic
tests. Since preconception carrier screening has been accepted by
various medical associations, DTC testing for these tests may be
regarded differently when compared with the DTC tests for
common disorders that have been criticized because of, for
example, the lack of clinical utility (i.e. how likely the test is to signiﬁ-
cantly improve patient outcomes) and analytical validity (i.e. how accu-
rately and reliably the test measures the genotype of interest).
Therefore, the aim of this article is to discuss various ethical issues
raised by the DTC offer of preconceptional carrier tests for autosomal
recessive disorders from commercial companies that are not
embedded in regular health care.
In the following order, this article will present and discuss: (i) the
current offer of preconceptional carrier tests through online providers;
(ii) the implications for the informed consent procedure and the
possible consequences for the provision of information; (iii) the
need for medical supervision and follow-up and (iv) the current
offer in relation to the appropriate use of existing resources.
The offer
Various commercial companies presently offer DTC carrier tests for
recessive genetic disorders. The details of the offer from each
company, however, vary greatly. In May 2010, the company DNA
Direct (www.dnadirect.com) advertised one individual carrier test
(for CF) and one carrier testing panel (for Ashkenazi Jews). On its
website the company underscored that ‘professional medical groups
including the NIH (...) and ACOG recommend that CF carrier
screening be offered to all couples who are planning a pregnancy
or are currently pregnant’ (https://www.dnadirect.com/web/article/
testing-for-genetic-disorders/cystic-ﬁbrosis/30/who-should-consider-
testing accessed 19/01/2011). The company DNATraits says that they
are ‘committed to making all medically validated tests available to con-
sumers rapidly, inexpensively and understandably’ (www.dnatraits.
com/compare accessed 03/05/2010) and is selling a limited
number of individual tests (e.g. for Alpha-1-Antitrypsin Deﬁciency)
as well as panels of disorders (e.g. an Ashkenazi Jewish Genetic
Disease Panel or a sickle cell/beta-thalassaemia panel). Along with
risk assessment information for other disorders, Pathway Genomics
(www.pathway.com) and 23andMe (www.23andme.com) include in
their full genome testing report the carrier status for 37 and 24 differ-
ent single-gene conditions, respectively. Finally, in February 2010 the
company Counsyl (www.counsyl.com) launched their offer of a pre-
pregnancy ‘Universal Carrier Test’ which tests an individual or
couple for over 100, mostly autosomal recessive, genetic diseases.
Counsyl considers these activities as ‘a cause, a campaign to
ﬁnally end the needless suffering of preventable genetic disease’
(https://www.counsyl.com/about/counsyl/ accessed 19/01/2011).
These abovementioned DTC genetic tests providers do not make a
distinction between screening individuals with an a priori low popu-
lation risk or testing individuals with a high a priori probability of
having an affected child. Because of this increasing possibility for deter-
mining an individuals’ risk of transmitting a condition to his or her off-
spring and the potential opportunities and threats generated by these
results to individual citizens and society as a whole, the Health Council
of the Netherlands (2008), for example, emphasized the need for cri-
teria for a responsible offer of genetic DTC screening as well. In this
speciﬁc report, the original genetic screening criteria, as outlined by
the WHO (Wilson and Jungner, 1968), which relate to the prerequi-
sites for starting community-wide screening, are extended with a
much larger view on screening. Not only are ‘speciﬁc individuals
being invited to undergo a medical test’ included in the deﬁnition of
a genetic carrier screening programme, but also a wider population
is included by ‘highlighting the opportunity to be tested in brochures
or in the press, via advertising or promotion by commercial providers’.
Screening can take the form of large-scale programmes for which all
pregnant women, all newborn babies or all men or women in a par-
ticular age group are eligible. But it can also entail ‘people responding
to an advertisement or a website offer for a health check with a clinic
or a health organization’ (Health Council of the Netherlands, 2008).
The large number of monogenic disorders included in the DTC
genetic testing companies’ services is in clear contrast with the
selected number of disorders that is usually considered for inclusion
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health care system. On the basis of generally accepted genetic screen-
ing guidelines (Health Council of the Netherlands, 2008; European
Society of Human Genetics, 2003; UK National Screening Committee,
2003; Nufﬁeld Council on Bioethics, 2006), carrier testing for a larger
number of disorders challenges at least two established speciﬁcations
that have been followed in this ﬁeld until now: (i) the condition should
be an important health problem, and (ii) there should be a suitable test
with known predictive value. Moreover, testing should lead to a
favourable ratio of advantages to disadvantages, in which the voluntary
character of consent, the information provision, the embedding in
medical supervision and the appropriate use of existing resources
are guaranteed (see below).
First,an importantcriterionthatshould befulﬁlled before ascreening
programme is initiated is that the condition should be an ‘important
health problem’ (European Society of Human Genetics, 2003; UK
National Screening Committee, 2003) or a ‘signiﬁcant health problem’
(Health Council of the Netherlands, 2008). It has been emphasized
that ‘importance’ or ‘signiﬁcance’ does not necessarily relate to the
number of people affected; it also addresses the severity of a health
problem even if a condition is rare (European Society of Human Gen-
etics, 2003; Health Council of the Netherlands, 2008). The Universal
Carrier Test offered by Counsyl, however, includes over 100 diseases.
The salient question, therefore, is whether DTC carrier testing should
be seen as an activity for which these screening criteria are applicable.
It is then debatable whether every condition included could fulﬁl these
genetic screening criteria. A disorder such as Gaucher Disease, for
example, was already a matter of debate with regard to its integration
in a panel for Ashkenazi Jews, since the most common Gaucher
Disease mutation in this population leads to a highly variable but
usually milder phenotype (Zimran et al., 1997; Zuckerman et al.,
2007). This then raises the question of whether it is acceptable to sys-
tematically identify carrier couples for disorders that are less severe
(Borry et al., 2008). Severity judgments are complex and a particularly
challenging base on which to make reproductive choices. Providing
severe and possibly less severe disorders within the same panel under-
mines the consistency of that panel.
Secondly,ithasbeenemphasizedthatscreeningshouldbebasedona
‘simple, safe, precise and validated test’ (UK National Screening Com-
mittee, 2003) ‘with known predictive value’ (European Society of
Human Genetics, 2003). Although the analytical validity of the test for
eachmutationincludedinpanelsofferedbyDTCgenetictestingcompa-
nies has likely been validated, the clinical validity (i.e. how consistently
and accurately the test detectsor predictsthe intermediateor ﬁnal out-
comes of interest) of the panel of mutations may be far from 100%.
Moreover, the clinical utility of testing for some disorders is debatable
as some homozygotes, because of low penetrance, may never
develop overt disease and/or the expression may be variable (Leven-
son, 2010). For example, this is the case for hereditary haemochroma-
tosis, which is also included in the Counsyl test panel. In addition,
companiesofferinglargepanelsofdisordersmaybasetheirinclusioncri-
teria on technical and economic aspects rather than on policy consider-
ations, which take into account, among other things, carrier frequency,
severityofthedisorderandfeasibilityoftestinginaparticularpopulation.
Italsoraisesdoubtsabouttheindividualdisordersincludedintheselarge
testing panels, and questions whether ‘more is really better’ (Leib et al.,
2005). Moreover, the question is raised of whether good information
and informed decision-making is still possible when the test panel con-
tains such a heterogeneous group of disorders, for which test sensitivity
and speciﬁcity are variable.
The need for good information
To ensure informed decision-making, it is crucial that individuals
receive the necessary information about the purpose of the test, the
reproductive choices resulting from the test, the reliability and limit-
ations of the test, the possible psychological impact and the potential
consequences of the test for the individual and his/her family
members (McQueen, 2002). Privacy and conﬁdentiality of the
results, as well as possible consequences related to their disclosure
to third parties, such as insurance companies and employers, should
also be discussed. Moreover, the nature of the reproductive options
makes it imperative to adopt a non-directive approach with potential
users. Although some DTC genetic testing companies do include a lot
of this information on their websites, the question is whether, while
being commercially driven, the information presented is balanced
enough to enable informed choice. Moreover, according to a recent
study (Lachance et al., 2010), many users would struggle to ﬁnd and
understand the important information on companies’ websites
needed to make an informed decision. Finally, although all companies
selling DTC genetic tests require some form of consent from the con-
sumer when ordering a test, the process of informed decision-making
cannot be reduced to clicking a box to accept the terms of service or
signing a document.
Educating people about carrier testing is complicated. The limited
knowledge of genetics in the general population (Molster et al.,
2009), and the fact that carrier tests have a test sensitivity of
,100% (causing a residual risk to people who are not found to be car-
riers) make the goal of transmitting information about these tests a
non-trivial matter. Studies have shown that a signiﬁcant proportion
of participants who tested negative when undergoing preconceptional
screening for CF or HbPs wrongly believed that they were deﬁnitively
not carriers, while some carriers falsely believed that they were only
likely to be carriers (Axworthy et al., 1996; Honnor et al., 2000; Hen-
neman et al., 2002). An offer of DTC testing is likely to face the same
problems in educating people as has been demonstrated in these
screening programmes. Multiple studies have also demonstrated that
both carriers and non-carriers may experience negative feelings,
such as anxiety and worry, when participating in genetic screening,
although anxiety levels often decrease after a few months (Bekker
et al., 1994; Henneman et al., 2002).
The DTC offer of genetic tests is worrisome in the light of these
ﬁndings, where the practices of existing DTC genetic testing compa-
nies mainly only offer written information found on their website.
As DNA Direct puts it: ‘Pretest education is provided at no additional
charge through in-depth, online materials for all tests’ (www.dnadirect.
com/web/consumers accessed 4/05/2010). Pre- or post-test
counselling is often only possible at an additional cost ($250/hour
for DNA Direct; $99/hour for Pathway Genomics), which may be a
barrier for consumers to ask for it, although some insurance compa-
nies may reimburse it. In contrast, DNATraits offers a free optional con-
sultation with their genetic counsellors before testing and a free
mandatory consultation after to discuss the results (http://www.
dnatraits.com/services accessed 04/05/2010). 23andMe does not
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advice of health professionals’ if questions or concerns arise
(https://www.23andme.com/about/consent/?version=1.3 accessed
19/01/2011). Similarly, Counsyl initially considered their test as an
‘at-home carrier test, as a successor to the at-home pregnancy test’
and did not consider offering any pre- or post-test counselling (http
://precedings.nature.com/documents/4192/version/1 accessed 19/
01/2011).
Medical supervision and
follow-up
It has been suggested that general practitioners or midwives may be
the most appropriate health care providers to offer carrier screening,
since they can provide preconception care as part of ongoing primary
care (Poppelaars et al., 2004b). In addition, some carrier screening
programmes are offered by gynaecologists or midwives in antenatal
care. Embedding in a healthcare setting can ensure adequate infor-
mation provision to increase informed choice, a more optimal
informed consent procedure, a medical follow-up if necessary and psy-
chosocial counselling.
An offer of carrier testing through the Internet by commercial com-
panies runs the risk of disconnecting the service completely from its
usual embedding in a medically supervised context. When these com-
panies started to offer carrier tests, they referred consumers to seek
medical supervision in the established health care system at the con-
sumer’s own discretion. Pathway Genomics suggested ‘You should
consult with a physician or other appropriate health care professional
regarding the diagnosis, treatment and prevention of any disease or
health condition’ (http://www.pathway.com/more_info/terms_of_
service accessed 04/05/2010). At the start of offering their service,
Counsyl also sent out this message by underlying that people could
order the test directly from their website to receive your kit immedi-
ately. ‘Everyone has a prescription: the ACMG recommends that
adults of reproductive age be offered carrier testing for CF and
spinal muscular atrophy, two of the many conditions assayed by the
Universal Genetic Test. Alternatively, you may get the test through
your doctor’ (https://www.counsyl.com/learn/easy/ accessed 04/
05/2010). Counsyl recently changed its stance and since the beginning
of May 2010, testing can only be requested through a physician, who
can be found, among others, via the list offered on Counsyl’s website.
The company also sends the results directly to the physician for
interpretation, thereby, technically no longer selling (but still advertis-
ing) tests directly to consumers. In October 2010, DNA Direct also
changed its policy; one can ﬁnd on their website that they ‘are no
longer offering testing services directly to consumers’; but are now
focusing their ‘efforts on providing comprehensive yet easy-to-under-
stand information and tools to consumers, physicians, hospitals,
employers and health plans’ (http://www.dnadirect.com/web/
consumers accessed 04/11/2010). Pathway Genomics has also, in
the last few months, changed the way they offer tests; consumers
must now obtain a physician prescription and the company offers con-
sumers the opportunity to send an email to the treating physician of
the consumer directly from the company site in order to request
the prescription. The offer through physicians may eliminate some
of the concerns that were raised about information provision, but
does not solve the issue about the appropriateness of the test
provided.
The absence of medical supervision for some DTC tests may
compromise or fail to foster patient health especially in the case of
carrier couples who may need intensive counselling regarding their
reproductive choices, as well as concerning the risks for other family
members.
The appropriate use of existing
resources
As preconceptional carrier screening programmes have an impact
on healthcare budgets, careful consideration should be given to
whether the expenses for such a programme are justiﬁed within
the realm of the healthcare system (Modell and Kuliev, 1991).
Namely the option for and the cost of a speciﬁc screening pro-
gramme might mean that other forms of screening cannot be
carried out. Usually a balance should be made between the
health gain obtained and the costs incurred. In the context of pre-
conceptional carrier screening this has to be analysed carefully, as
the primary goal of preconceptional carrier screening is enabling
informed reproductive choice. Furthermore, the identiﬁcation of a
high number of carriers or false positives may create a higher
number of visits to medical doctors for more information, and
thus leading to higher costs in follow-up activities. Commercial
companies underline that most users will pay for this test ‘out of
pocket’ and therefore, the health care system will not be burdened.
Since the need for follow-up information or tests is likely to happen
in the traditional health care system, this is not completely true. It
is foreseeable that companies testing for a whole list of disorders
will create a higher number of patients visiting health services.
For example, for the test panel offered by Counsyl, the company
foresees that 35% of the participating individuals would be car-
riers of at least one disease.
Furthermore, every mentioned company underlines the value of
privacy and the possibility to perform the test outside the control of
insurers or the healthcare system. They often play on people’s fear
that if testing is conducted within the traditional health care system,
third parties could access their genetic information and that this
might lead to discrimination. As expressed by Counsyl, ‘no one will
ever have access to your data without your express consent’ (https://
www.counsyl.com/about/privacy/ accessed 04/05/2010). Pathway
Genomics states that ‘Your DNA and results belong to you and no
one else. Nobody should see your data or results unless you
want them to’ (http://www.pathway.com/more_info/dna_security
accessed 04/05/2010). In contrast, DNA Direct and Counsyl want
health insurers to be involved in their services. DNA Direct underlines
that their services will be reimbursed by most insurers, although insur-
ance companies may still ask for a letter of medical necessity which
people with no a priori high risk may have. Counsyl advances that ‘for
many people the test will be entirely free [paid by the insurer]; for
many others insurance will cover 70% or more of the cost’. In
contrast, DNATraits refuses any reimbursement: ‘DNATraits does
not accept reimbursement from insurance companies as this might
limit our ability to ensure your privacy’ (http://www.
dnatraits.com/philosophy accessed 04/05/2010). As it is to be
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bursed by insurance companies for their customers, it becomes
crucial that carrier tests involve a required degree of usefulness,
have a scientiﬁc basis and are voluntary in nature.
Conclusion
The implementation of a preconceptional carrier test should result in
the optimization of the advantages whilst reducing as much as possible
the risks or adverse effects of the offer. Therefore, it is crucial that the
tests offered for important health problems are suitable and have a
known predictive value. Furthermore, it is important to ensure
quality pre- and post-test information and counselling that can lead
to informed decision-making for the participants. All potential negative
psychosocial impacts resulting from participation in a carrier test
should be avoided or minimized and the testing process should lead
to a correct understanding of the test result. In our opinion, a com-
mercial offer of DTC genetic carrier testing through the Internet
makes it difﬁcult to meet all these criteria.
The purpose of carrier screening is to enlarge people’s reproductive
autonomy by enabling carrier couples to make informed reproductive
decisions. In this paper, we have criticized DTC genetic testing com-
panies that have included large numbers of disorders in the test panel,
including less severe ones, as well as disorders for which only subop-
timal tests are available according to the traditional screening criteria.
It is, however, questionable whether commercial (preconceptional)
carrier test providers can continue to exist using this business model
as long as such genetic carrier tests are not integrated in larger,
more comprehensive prenatal, or preferably in preconceptional,
care settings (which are, admittedly, not really established in general
healthcare yet). The company University Diagnostics Ltd (www.
udlgenetics.com, only to be consulted on http://www.archive.org/),
for example, started to offer a service to discover CF carrier status,
but has ceased to exist (Advisory Committee on Genetic Testing,
1999). Furthermore, an analysis of the companies’ activities in this
ﬁeld shows that various genetic tests that were marketed online in
recent years are no longer available for purchase. Without the
support of the healthcare system, it may be that only a relatively
small percentage of the population will become aware of these ser-
vices and will use them (Kolor et al., 2009).
That being said, involving a physician in the DTC offer of genetic
tests may not solve many of our concerns. If physicians are not well
educated about which tests should be given based on speciﬁc cri-
teria, they may simply become a pawn in the commercial compa-
nies attempt at increasing their market size. It will also be
important to see how the regulatory frameworks will evolve.
Various recent events have created the expectation that regulatory
oversight will increase in the near future (Borry et al., 2010). For
example, the European Society of Human Genetics recently
endorsed a statement in which it recommended to ensure,
among other issues, the quality of the testing services, the provision
of pretest information and genetic counselling, a face-to-face consul-
tation and oversight of this industry (European Society of Human
Genetics, 2010). As the government has a duty to protect citizens
against the risks of unsound testing, the government can be
expected to ensure that speciﬁc standards are being held and to
promote the responsible provision and responsible use of speciﬁc
genetic testing services to the public. If we agree that reproductive
autonomy should be respected, carrier screening for various serious
disorders should be available, but careful implementation is necess-
ary in order to ensure optimization of the screening offer, counsel-
ling and follow-up.
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